Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinician-reviewed guide to delayed-onset side effects of methimazole (Tapazole), including agranulocytosis, hepatotoxicity, vasculitis, and ANCA-associated disease, with dosing context, trial data, and FDA label guidance.
Read clinical reviewA comprehensive review of methimazole (Tapazole) adverse event incidence rates from clinical trials, FDA labeling, FAERS data, and post-market literature, with specific percentages, named studies, and clinical guidance.
Read clinical reviewA clinician-reviewed guide to methimazole (Tapazole) side effects, with special focus on potentially permanent adverse events including agranulocytosis, aplastic anemia, liver damage, and vasculitis, backed by FDA labeling, FAERS data, and primary trial evidence.
Read clinical reviewA clinician-reviewed guide to the rare but serious adverse events linked to methimazole (Tapazole), including agranulocytosis, hepatotoxicity, vasculitis, and teratogenicity, with trial data, FAERS reports, and FDA label citations.
Read clinical reviewA clinical breakdown of methimazole adverse events by frequency, severity, and patient phenotype, covering agranulocytosis risk, hepatotoxicity, teratogenicity, and dose-dependent effects with primary-source citations.
Read clinical reviewA physician-reviewed guide to methimazole (Tapazole) withdrawal and discontinuation syndrome, covering rebound hyperthyroidism, agranulocytosis risk, tapering strategies, and post-market safety data from FAERS and clinical trials.
Read clinical review